{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T03:12:36Z","timestamp":1772766756692,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Arrhythmia"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Direct oral anticoagulants (DOACs) are the recommended first\u2010line therapy for ischemic stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). However, the safety and effectiveness of edoxaban for this indication requires monitoring over the long term in real\u2010world settings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>ETNA\u2010AF\u2010Japan (trial no. UMIN000017011) was a prospective, multicenter observational study (part of postmarketing surveillance in Japan). NVAF patients due to receive edoxaban to prevent ischemic stroke were enrolled between 13 April 2015 and 30 September 2017.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 11\u00a0569 patients were enrolled. For the 11\u00a0111 patients (female, 40.6%) whose data comprised the safety analysis set, age, body weight, creatinine clearance (CLcr), and CHADS<jats:sub>2<\/jats:sub> score were 74.2\u00a0\u00b1\u00a010.0\u00a0years, 60.0\u00a0\u00b1\u00a012.7\u00a0kg, 63.9\u00a0\u00b1\u00a025.8\u00a0mL\/min, and 2.2\u00a0\u00b1\u00a01.3, respectively (mean\u00a0\u00b1\u00a0SD). The majority (86.3%) received edoxaban in accordance with package insert information. The mean duration of treatment was 561.9\u00a0\u00b1\u00a0261.2\u00a0days. The annual incidence (95% confidence interval) of all bleeding events and major bleeding events was 5.60% (5.25%\u20135.98%) and 1.02% (0.88%\u20131.18%), respectively. The annual incidence of ischemic stroke (excluding transient ischemic attack, TIA) or systemic embolism was 1.08% (0.93%\u20131.25%). Multivariate analysis showed low body weight, low CLcr, history of gastrointestinal bleeding, anemia, and use of an antiplatelet agent to be associated with major bleeding, and history of ischemic stroke or TIA, vascular disease, and antiplatelet agent use to be associated with ischemic stroke (excluding TIA) or systemic embolism.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These results provide real\u2010world evidence for the long\u2010term good safety and effectiveness profile of edoxaban in Japanese NVAF patients under clinical practice.<\/jats:p><\/jats:sec>","DOI":"10.1002\/joa3.12520","type":"journal-article","created":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T13:02:32Z","timestamp":1614171752000},"page":"370-383","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Safety and effectiveness of edoxaban in Japanese patients with nonvalvular atrial fibrillation: Final report of a two\u2010year postmarketing surveillance study (ETNA\u2010AF\u2010Japan)"],"prefix":"10.1002","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2544-8464","authenticated-orcid":false,"given":"Takeshi","family":"Yamashita","sequence":"first","affiliation":[{"name":"The Cardiovascular Institute Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiro","family":"Koretsune","sequence":"additional","affiliation":[{"name":"National Hospital Organization Osaka National Hospital Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9846-2729","authenticated-orcid":false,"given":"Tomoko","family":"Nagao","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology &amp; PMS Department Daiichi Sankyo Co. Ltd Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhito","family":"Shiosakai","sequence":"additional","affiliation":[{"name":"Data Intelligence Department Daiichi Sankyo Co. Ltd Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,2,24]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310907"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-66-0092"},{"key":"e_1_2_10_7_1","unstructured":"OnoK IwasakiY ShimizuW.JCS\/JHRS 2020 Guideline on pharmacotherapy of cardiac arrhythmias.The Japanese Circulation Society\/Japanese Heart Rhythm Society Joint Guidelines. Available fromhttps:\/\/www.j\u2010circ.or.jp\/old\/guideline\/pdf\/JCS2020_Ono.pdf[In Japanese]"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy136"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0261-1"},{"key":"e_1_2_10_10_1","unstructured":"DailyMed[internet].SAVAYSA \u2013 edoxaban tosylate tablet film coated. [updated 24 Apr 2020; cited 1 Sep 2020]. Available fromhttps:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=e77d3400\u201056ad\u201011e3\u2010949a\u20100800200c9a66"},{"key":"e_1_2_10_11_1","unstructured":"Electronic medicines compendium (EMC)[internet].Lixiana 60 mg film\u2010coated tablets. [updated 23 Jul 2020; cited 1 Sep 2020]. Available fromhttps:\/\/www.medicines.org.uk\/emc\/product\/6905\/smpc#gref"},{"key":"e_1_2_10_12_1","unstructured":"Pharmaceuticals and Medical Devices Agency[internet].Lixiana OD tablet Japanese package insert. [updated Jan 2020; cited 1 Sep 2020]. Available fromhttps:\/\/www.info.pmda.go.jp\/go\/pack\/3339002F4029_1_04\/"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joa.2012.07.001"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2008.06.029"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/joa3.12149"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/joa3.12332"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0134"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.22.2864"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-1584"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-15-0574"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12683"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2018.12.013"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007633"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2019.07.007"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-18-0991"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-019-01934-6"}],"container-title":["Journal of Arrhythmia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/joa3.12520","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/joa3.12520","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/joa3.12520","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T15:38:29Z","timestamp":1693582709000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/joa3.12520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,24]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1002\/joa3.12520"],"URL":"https:\/\/doi.org\/10.1002\/joa3.12520","archive":["Portico"],"relation":{},"ISSN":["1880-4276","1883-2148"],"issn-type":[{"value":"1880-4276","type":"print"},{"value":"1883-2148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,24]]},"assertion":[{"value":"2020-12-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}